Ligand PharmaceuticalsLGND
LGND
About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Employees: 68
0
Funds holding %
of 7,202 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
16% more call options, than puts
Call options by funds: $999K | Put options by funds: $860K
12% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 86
10% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 29
0% more capital invested
Capital invested by funds: $1.95B [Q4 2024] → $1.96B (+$3.5M) [Q1 2025]
0.05% more ownership
Funds ownership: 96.43% [Q4 2024] → 96.48% (+0.05%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% less funds holding
Funds holding: 254 [Q4 2024] → 253 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$143
36%
upside
Avg. target
$144
37%
upside
High target
$145
38%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Trevor Allred | 38%upside $145 | Outperform Maintained | 9 May 2025 |
Stifel Annabel Samimy | 36%upside $143 | Buy Initiated | 10 Apr 2025 |
Financial journalist opinion
Based on 5 articles about LGND published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025.
Neutral
Seeking Alpha
1 week ago
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chief Executive Officer Rich Baxter – Senior Vice President-Investment Operations Tavo Espinoza – Chief Financial Officer Lauren Hay – Vice President-Strategic Planning and Investment Analytics Conference Call Participants Doug Miehm – RBC Capital Markets Matt Hewitt – Craig-Hallum Trevor Allred – Oppenheimer Annabel Samimy – Stifel John Vandermosten – Zacks Operator Thank you for standing by. My name is Kate and I will be your conference operator today.
Neutral
GlobeNewsWire
1 week ago
Ligand Reports First Quarter 2025 Financial Results
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.
Neutral
GlobeNewsWire
2 weeks ago
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.
Neutral
GlobeNewsWire
3 weeks ago
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025.
Neutral
GlobeNewsWire
1 month ago
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fla. and FREEHOLD, N.J.
Neutral
GlobeNewsWire
2 months ago
Ligand to Participate in March Investor Conferences
JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami).
Neutral
Seeking Alpha
2 months ago
Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - CEO Paul Hadden - Senior Vice President of Investments and Business Development Tavo Espinoza - Chief Financial Officer Lauren Hay - Vice President of Strategic Planning and Investment Analytics Conference Call Participants Matt Hewitt - Craig-Hallum Joseph Pantginis - HC Wainwright Douglas Miehm - RBC Capital Markets Trevor Allred - Oppenheimer Larry Solow - CJS Securities John Vandermosten - Zack Melanie Herman Good morning everyone and welcome to Ligand's Fourth Quarter and Full Year 2024 Earnings Call. During the call today, we will review the financial results we released earlier today and provide commentary on our partner pipeline and business development activity, followed by a question and answer session.
Neutral
GlobeNewsWire
2 months ago
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla.
Neutral
GlobeNewsWire
2 months ago
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi (FCX-007), Castle Creek's lead candidate, in patients with dystrophic epidermolysis bullosa (DEB).
Charts implemented using Lightweight Charts™